| Ytd | -35.23% | |
| 1y | -89.02% |
| Open | 2.82 | Prev Close | 2.86 | Low | 2.70 | High | 2.92 | Mkt Cap | 26.83M |
| Vol | 277.83K | Avg Vol | 2.25M | EPS | -3.10 | P/E | -0.92 | Forward P/E | N/A |
| Beta | 0.39 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-08 | 50-d Avg | 3.07 | 200-d Avg | 5.06 | 1yr Est | 0.00 |
TVRD News
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular
Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerabilit
Tvardi Therapeutics stock dips premarket as investors take profits after positive Phase 1 data for T
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's
Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-mark
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's
Raymond James analyst Ryan Deschner upgrades Tvardi Therapeutics (NASDAQ:TVRD) from Market Perfor
Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prod
Tvardi Therapeutics (TVRD) stock jumps 50% after reporting positive Phase 1 data for its next-gen ST
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tues
BTIG analyst Julian Harrison reiterates Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and maintain
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions i
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions i
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 284.8% to $11.39 during Monday
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday&
Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announ
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday&
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a cli
Topline results from healthy volunteer study and clinical development strategy for next-generation
Tvardi Therapeutics, Inc. (NASDAQ: TVRD - Get Free Report) has received an average recommendation of
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a c
Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 20
Shares of Tvardi Therapeutics, Inc. (NASDAQ: TVRD - Get Free Report) have been given a consensus rat
Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium Presentati
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suf
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suf
NEW YORK--(BUSINESS WIRE)---- $TVRD #Faruqi--Faruqi & Faruqi, LLP, a leading national securities law
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suf
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suf
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suf